1.
Clinical Research in India
Drivers for changing perceptions
Dr Dilip Pawar
MD, PhD, MCSEPI, DPBM, DCA, MASCPT(USA),
MASPET(USA), FCP(USA), MBA
Fellow Of American Society Of Clinical Pharmacology
Director & Chief Scientific Advisor
Institute of Clinical Research Education and Research
Chief Executive Officer & Global Medical Director
Drug Research Laboratory; MUMBAI, INDIA
Dr Dilip Pawar 1

2.
WELCOME
Dr Dilip Pawar 2

3.
Dr Dilip Pawar 3

4.
INDIA
POPULATION
URBAN 345 million
LIFE EXPECTANCY
Total 1 billion
68 YEARS
INDIA
EXPENDITUR ON HEALTH
E
URBAN LITERACY
6%OF GDP
MALES 82%
(1.2% Government Spend)
FEMALES 64%
•Fourth largest economy in the
world
•Second fastest growing economy in BIRTH RATE 27 per 1000
the world DEATH RATE 8 per 1000
•Projected GDP growth rate – 8% INFANT MORTALITY 77 per 1000
•Healthcare, Pharma, Biotech, IT,
BPO, telecom are fastest growing
Dr Dilip Pawar 4
sectors

5.
Life Span
119
120
Population >65 years (million)
100
80 72
62
58
60
Life Expectancy 42
32
40
20
0
1947
1980
1998
2020
2025
1991
Dr Dilip Pawar 5

6.
Population – Pronounced
Rural to Urban Migration
2000 (1000mn) 2025 (1400 mn)
218 mn
1990 (846 mn)
340 mn
Prevalence of Illness
10% 22%
• Rapid recruitment 15-60 years > 60 years
(20-30% time advantage if
studies are conducted in India URBAN POPULATION
– Ernst & Young)
PREVALENCE OF ILLNESS
Dr Dilip Pawar 6

7.
Changing Disease
Patterns
DISEASES OF DEVELOPED WORLD
DISEASES OF DEVELOPING COUNTRIES
PROBLEMS OF
REPRODUCTIVE AIDS
HEALTH
CHRONIC DISEASES
ACUTE LIFESTYLE-RELATED
INFECTIOUS
DISEASES CARDIO-VASCULAR
NUTRITIONAL CANCERS
DISEASES DEGENERATIVE DISEASES
Epidemiologic Transition
•Varied Disease Patterns
of developing and
developed world
Dr Dilip Pawar 7

8.
Diseases and Patients
Changing Disease Patient Population
 8 million Epileptics
Patterns
 40 million Asthmatics
Cardiovascular diseases
 ~34 million Diabetics
 Degenerative neurological
diseases  8-10 million HIV +ve
 Diabetes  3 million Cancer patients
 Cancer  > 2 million Cardiac deaths
 Psychiatric illnesses  1.5 million Alzheimer
 Gastro Intestinal Disorders patients
 Infectious Diseases  1 million PD patients
 Tropical diseases  15% Hypertensive
1% Schizophrenia patients

India has diseases of the tropical world plus diseases of
the developed countries
Dr Dilip Pawar 8

9.
India – Ethnic Diversity
Successive waves of visitors / invaders from the North – Dravidians
driven southwards
 Aryans from Central Asian steppes – 1500 BC
(pale skinned and light-eyed)
 Greeks (Yavanas) Today
 Scythians Caucasians 80%
 Parthians Dravidians 20%
 Iranians (Persians)
 Also Turks, Huns, Chinese, Ethopians • Ethnic diversity
- majority Caucasian
Later Portuguese, Dutch, French, Moghuls (Mongols), English
Dr Dilip Pawar 9

10.
The ‘Language’ Advantage
Languages - 15 official languages
Hindi - National language
- Mother tongue of 30% of
people
English - Language for communication
• Hospital Management
Teaching - Medical,
Nursing & Pharmacy • Source documents
ENGLISH
Communication with
Regulatory Authorities Labeling of Medicines
Dr Dilip Pawar 10

11.
Medical Practice in
India
 Multiple systems
 Ayurveda
 Other traditional Indian systems
 Homeopathy
 Western system; most widely practiced
 Multiple systems of therapies
Dr Dilip Pawar 11

12.
Pharmaceutical industry-
Past
 Clinical trials not mandatory till 1987
 Market of branded generics
 No incentive for research
 Innovator companies indifferent
 Local industry not serious about
clinical trials
 No data exclusivity & patent
protection
Dr Dilip Pawar 12

13.
Medical profession
 Did not question source of references
 Did not demand local evidence
 Patient care Ist priority
 Not familiar with GCP needs
 Did government funded research
 Lack of appreciation of mutual needs
Dr Dilip Pawar 13

14.
IRBs
 Very few in number
 Mainly reviewed animal studies &
post graduate theses
 Not US FDA compliant
 No SOPs
 Not much attention paid to ICF
 Patient reimbursement not permitted
Dr Dilip Pawar 14

15.
Why Not India until recently?
 High importation duty (55%)
 No provision in drug laws for global
studies
 No incentive for PI’s; academic
institutions suspicious of clinicians
 No Data Exclusivity
 Long start up times
Dr Dilip Pawar 15

16.
Changing perceptions
and a new environment
 Drivers:
 WTO
 Need to globalize
 Encourage Private public partnership
 Intense lobbying by MNCs
 Shift of focus of the indigenous industry;
from process to product
 Economic sense
Dr Dilip Pawar 16

17.
OUTSOURCING OPPORTUNITIES
- INDIA
Bulk Drugs Contract
Contract & Marketing &
R&D Formulations Sales
Manufacturing
Medicinal International
Chemistry Clinical
Trials
Plant Outsourcing
Machinery Opportunities - Technical
& India Services
Pharma
Equipment
Primary Herbals
Packaging Neutraceuticals
Bioinformatics
Materials Biostatistics
Software
Development
Dr Dilip Pawar 17

18.
Why India Now?
 No importation duty
 Patent act amended; IPR in place
 Data Exclusivity –
 Export procedures simplified
 Drug laws amended to permit global
studies
Dr Dilip Pawar 18

19.
Why India…..
 GCP compliant IRB’s
 Untapped patient population
 English business language
 GCP guidelines ICH compliant
 Start up time reduced to 8-12 weeks
 CAP certified central labs
Dr Dilip Pawar 19

20.
Clinical Trial Environment
Change Drivers
Government and Regulatory Environment more conducive to clinical research
• GCP guidelines introduced by ICMR and DGHS
• Customs levies on clinical trial drug supplies eliminated
Patent rules harmonised Healthcare and Healthcare delivery
improvements
• Tertiary Hospital Infrastructure
• GCP awareness
• Healthcare Industry - Rs.100,000 crores
Epidemiological Transition of • Growing demand by Middle Class
Disease - Patterns changing
• Good connectivity
• Increasing use of IT and Internet
Health Insurance expansion • Transfer of ECGs and Imaging - now routine
- private participation
emphasis on preventive care
Good Courier Systems within India
and to other countries
Dr Dilip Pawar 20

21.
Skilled workforce
High quality research with
domain expertise
Maintenance of
time schedules
INDIA Shortening time
to market
Therapeutic Expertise Technology support
Dr Dilip Pawar 21

22.
Regulatory milestones
 Mandatory clinical trials for the first
applicant – 1987
 BE for subsequent applicants – 1987
 GCP committee formed – 1995
 Ethical guidelines - 2000
 GCP guidelines released – 2001
 Drug laws amended to permit
simultaneous phase global trials -
2005 Dr Dilip Pawar 22

23.
Recipe for success in India
 MOH approval easy if US IND/ EMEA
application
 Understand PI behavior – financial
negotiations
 Invest in training PIs, IRBs
 Promote young, enthusiastic PIs
Dr Dilip Pawar 23

24.
Nascent but Fast Growing
- India’s Clinical Development Sector -
 Annual Revenues USD 120 M with 40% growth in
past year
 240 international studies recruiting subjects = 1.2%
of the total studies worldwide
 66% of international clinical trials are Phase III
 207 sites FDA registered
 40,000 subjects participated in clinical trials to date
(<0.02% of population)
Dr Dilip Pawar 24

25.
Recent India Regulatory Reform makes
Approvals Possible within 6 weeks.
Regulatory body Approval Time
Drugs Controller Regulatory approval for  4 weeks – FAST TRACK,
General of India (DCGI) study conduct in India US,UK,CANADA,SWITZERLA
ND,GERMANY,EMEA,
AUSTRALIA, JAPAN CTA
available
 16 weeks, no documentation to
support successful US/EU CTA
Drugs Controller Test license to import 2 weeks in addition
General of India (DCGI) trial supplies
Ethics Committees Local Ethics committee 6 – 8 weeks (in parallel)
approval by sites
Total (parallel processing) - 6-8 weeks – FAST TRACK
16 weeks (track B)
Directorate General of Permission to export Additional 2 to 4 weeks
Foreign Trade (DGFT) blood samples
Dr Dilip Pawar 25

26.
Meticulously Following Prescribed
Process Is Key.
Regulatory & IRB Approval Process:India
PI submits
CDA signed,
Consent Letter application Queries Approvals
Site Selected,
from PIs to EC from EC from EC
Release Protocol
reply to queries
Contract/LOI Approvals
executed from EC
All documents Sponsor / CRO
to PI
received
Regulatory Regulatory Regulatory DGFT
Internal review
dossier submission Approval Export License
of dossier
compilation to DCGI from DCGI Application
Export License
Submission
Obtained
to DGFT
from DGFT
Dr Dilip Pawar 26

27.
Don‘t set too ambitious
deadlines
Deadline is deadline !
Dr Dilip Pawar 27

28.
India — Gradually Building a
Track Record
Dr Dilip Pawar 28

29.
Clinical Trials Outsourced
to India
Differing Dynamics
I. Clinical Trials on diseases of topics e.g. Locations – usually outside urban areas
malaria, TB, leishmaniasis Benefits to India – likely / immediate
II. Clinical Trials on diseases/ disorders of a Sponsors – Industry and Others
primitive economy e.g. Locations – urban and perirural
 Acute infections Benefits to India – likely / immediate
 Nutrition-related
 Reproductive health-related
 AIDS
III. Clinical Trials on diseases/ disorders of a Sponsors – Industry
developed economy e.g. Locations – urban
 Cardiovascular Test molecules – drugs in development
 CNS including neurological degeneration and Data for regulatory submission
psychiatry Benefits to India – likely / immediate
 Gastrointestinal
 Diabetes
 Cancers Dr Dilip Pawar 29
 AIDS

30.
India offers Cost Saving
Potential
Overall Indexed Clinical Trial Costs
India 0.56
China 0.52
Russia 0.4
Australia 0.73
US 1
Spain 0.93
Germany 1.2
France 0.71
UK 1.09
Poland 0.77
0 0.2 0.4 0.6 0.8 1 1.2 1.4
Source: FastTrack Systems Global Cost Databases
Dr Dilip Pawar 30

31.
Mckinsey Report
Indian CR market will grow to US $1.5
billion in value by 2010.
Dr Dilip Pawar 31

32.
Choose Good Investigators
Need local understanding and
global experience
 India has experienced
Investigators
 Concern factors :
 Using Investigator groups (some will be
great, others might not)
 When inexperienced, assess willingness
and motivation to learn and then train
and retrain
Dr Dilip Pawar 32

33.
INDIA - Perceptions & Realities
Perception Reality
Many sites in India are trained in GCP – now
GCP awareness absent or low
mandated by Government
Various audits of the study show no adverse
finding
Data integrity in question
In India US FDA has audited sites with no major
comments
Different languages cause English used for all healthcare-related
confusion and escalate costs activities, systems, procedures and drug
because of need to translate labels. Only patient-related documents need
documents translation
Telecommunication facilities good in urban
Telecommunication poor areas. Connectivity good – EDC studies
Connectivity poor possible – electronic transmission of ECG,
imagings frequent.
Dr Dilip Pawar 33

34.
Is Clinical Research is an
attractive Option for
INDIA
Dr Dilip Pawar 34

35.
Key Messages
India is well placed to provide solutions for
contemporary and future clinical research
 Can facilitate affordable drug research
 Has required patient populations and qualified scientists
and clinicians
 Has the information technology competitive advantage
 Has a regulatory framework which is moving towards
regulatory harmonization
 The socio-economic transformation in urban India
understands contemporary GCP requirements
 Rapid urbanisation and exposure to developed world
facilitates cross-cultural understanding
 Product patents from January 1, 2005
Dr Dilip Pawar 35

36.
The Opportunities ahead
 In Clinical Research Opportunities are many
 Not Only in India but also internationally
 GRAB THE OPPORTUNITY…….
Dr Dilip Pawar 36

37.
Dr Dilip Pawar 37